IIT-M develops injectable hydrogel for fibrosis
Analysis based on 6 articles · First reported May 29, 2026 · Last updated May 30, 2026
The development of this injectable hydrogel by IIT Madras could significantly impact the pharmaceutical and healthcare industries by offering a more affordable and effective treatment for fibrosis and sarcopenia. This innovation has the potential to reduce treatment costs from USD 2,000-3,000 to around USD 300, making advanced therapies more accessible and potentially shifting market dynamics for existing treatments.
Researchers at the IIT Madras (IIT-M), including Vignesh Muthuvijayan>>> and Varshini Gopinath>>>, have developed a patented injectable hydrogel designed to treat fibrosis and other chronic degenerative diseases. This biodegradable and biocompatible hydrogel, made from silk cocoons and seaweed, delivers anti-fibrotic and anti-inflammatory drugs directly to affected tissues in a sustained manner, potentially replacing weeks of medication with a single localized dose. The innovation is estimated to reduce treatment costs from USD 2,000-3,000 to approximately USD 300 per course. Follow-up studies, in collaboration with the University of California, San Diego, have shown its potential in treating sarcopenia, an age-related muscle loss condition. The IIT Madras is exploring various pathways for real-world deployment, including technology transfer, licensing, or creating a start-up.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard